Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
DCPH was delisted on the 10th of June, 2024.
148 hedge funds and large institutions have $1.68B invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 59 increasing their positions, 41 reducing their positions, and 36 closing their positions.
84% more call options, than puts
Call options by funds: $15M | Put options by funds: $8.16M
44% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 41
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
8% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 36
3% less funds holding
Funds holding: 153 → 148 (-5)
24% less capital invested
Capital invested by funds: $2.22B → $1.68B (-$544M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$83.3M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$48M |
| 3 |
AG
Artal Group
Luxembourg
|
+$30.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$23M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$22.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$25.6M |
| 2 |
O
OrbiMed
New York
|
-$19.8M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$13.4M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$12.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12M |
DCPH Hedge Fund Activity: Q1 2020 in Review
148 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q1 2020, worth a combined $1.68B — down 24% from $2.22B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of DCPH and 33 opened new positions — a net loss of 3 holders — while 41 trimmed existing stakes and 59 added.
The largest buyer was Avoro Capital Advisors, adding an estimated $83.3M. The largest seller was Janus Henderson Group, cutting an estimated $25.6M.
- 148 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q1 2020, down from 153 in Q4 2019.
- Funds reported $1.68B of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q1 2020, down 24% quarter-over-quarter.
- 33 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q1 2020 and 36 closed out, a net change of -3 holders.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q1 2020 was Avoro Capital Advisors, an estimated $83.3M added.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q1 2020 was Janus Henderson Group, an estimated $25.6M sold.
Based on aggregated 13F filings for Q1 2020.